Table 1.
Characteristics of alloreactive and leukemia-reactive CD4+CD25+ T cells
| Pairs studied | Donor no./HLA match | Recipient no./alloreactive stimulators | Alloreactive CD4+CD25+ cells, % | Alloreactive CD4+CD25+ cells after IT treatment, % | Recipient no./leukemic stimulators | Leukemia-reactive CD4+CD25+ cells, % |
|---|---|---|---|---|---|---|
| 1 | 1/Yes | 1/PBMC | 2.32 | 0.08 | 1/AML | 1.57 |
| 2 | 2/No | 2/PBMC | 9.51 | 0.14 | 2/AML | 7.08 |
| 3 | 3/No | 2/PBMC | 6.39 | 0.11 | 2/AML | 4.70 |
| 4 | 4/No | 3/Act. T | 15.26 | 0.22 | 3/AML | 8.12 |
| 5 | 5/No | 4/Act. T | 12.16 | 0.16 | 4/AML | 7.80 |
| 6 | 2/No | 5/Act. T | 7.66 | 0.18 | 5/ALL | 3.87 |
| 7 | 3/No | 5/Act. T | 9.88 | 0.20 | 5/ALL | 6.81 |
| 8 | 4/No | 6/Act. T | 7.30 | 0.12 | 6/ALL | 4.15 |
| 9 | 5/No | 6/Act. T | 11.91 | 0.18 | 6/ALL | 6.15 |
Act. T, expanded activated T cells; ALL, acute lymphatic leukemia.